Quality of Life 1y and 2 y After VV-ECMO for COVID-19

University Hospital, Ghent28 enrolled

Overview

This study aims to investigate the quality of life and the outcome after veno-venous extracoporeal membrane oxygenation (ECMO) support fir severe acute respiratory syndrome (ARDS) in COVID-19 patients.

The investigators follow our COVID-19 patients supported by ECMO, we make phone calls or real-life visits to pthe patients to score the quality of life, by using the SF-36. The SF-36 measures eight scales: physical functioning, role physical, bodily pain, general health, vitality , social functioning , role emotional , and mental health. The participants are contacted 3 months, 6months, 1year and 2 years after the ECMO support started for evaluation of the SF-36.

Study Type

OBSERVATIONAL

Enrollment

Conditions

COVID-19 Acute Respiratory Distress Syndrome Extracorporeal Membrane Oxygenation Complication Quality of Life Death

Interventions

VV-ECMODEVICE

veno-venous extracorporeal membrane oxygenation

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with PCR-confirmed COVID-19 infection AND * Acute Respiratory Distress Syndrome who require veno-venous ECMO therapy. Exclusion Criteria: * None

Locations (1)

Ghent university hospital

Ghent, Belgium

Outcomes

Primary Outcomes

in-hospital mortality

Time frame: mortality during hospitalisation, up to two years

Quality of life 1y after ECMO insertion

Result of SF-36 1 year after VV-ECMO insertion

Time frame: 1 year

Quality of life 2y after ECMO insertion

Result of SF-36 2 years after VV-ECMO insertion

Time frame: 2 years

Secondary Outcomes

Lung complications requiring surgical treatment

Hemothorax or lung abcedation

Time frame: From the start of VV-ECMO support until weaning of VV-ECMO, up to two years

Duration of mechanical ventilation

Time frame: 2 years

LOS ICU

length of stay at the intensive care unit

Time frame: from the day of intensive care unit admission until the day of transfer to the ward, up to two years

LOS hospital

length of stay at the hospital

Time frame: from the day of hospital admission until the day that the participant is transferred to home, up to two years

death after hospital discharge

all-cause death

Time frame: after discharge from the hospital upon 2 years after

Incidence of acute kidney injury

Time frame: from the day of hospital admission until the day that the participant is transferred to home, up to two years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.